Omninano Pharmaceuticals

What Omninano Pharmaceuticals does

OmniNano Pharmaceuticals is a private, U.S.-based pharmaceutical company developing dual-mechanism nanomedicines engineered to synergistically target tumor cells and the tumor microenvironment. The company is headquartered in Missouri City, Texas, and operates as a pre-commercial drug development entity focused on solid tumors, with its lead asset ONP-001 advancing toward treatment of pancreatic cancer.

The company's core technology is a proprietary dual-mechanism micelle platform that co-delivers a chemotherapy payload and a stroma-modulating agent within a single nanocarrier. ONP-001 is designed to remodel the dense, fibrotic desmoplastic stroma that characterizes pancreatic tumors, reducing fibrosis, normalizing vasculature, relieving hypoxia, and depleting cancer stem cells while delivering localized chemotherapy. The mechanism is positioned as addressing the root cause of treatment resistance in solid tumors rather than simply increasing cytotoxic potency. Company materials also reference applicability to other treatment-resistant solid tumors beyond the lead pancreatic indication.

OmniNano is currently in the drug development stage with no approved or commercialized products and no disclosed revenue, pricing, or commercial distribution channels. Pricing is explicitly not applicable at this stage. The company maintains a professional website and direct email contact ([email protected]) as its primary commercial interface, consistent with a pre-clinical or early-stage entity relying on inbound inquiries for partnership and development discussions rather than active sales or marketing motion. No funding rounds, headcount figures, management team disclosures, partnerships, or regulatory milestones were disclosed in the available data.

Name

Omninano Pharmaceuticals

Legal name

OmniNano Pharmaceuticals

Website

https://omninanopharma.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

OmniNano Pharmaceuticals is a private U.S. biotech developing ONP-001, a dual-mechanism nanomedicine that co-delivers chemotherapy and a stroma-modulating agent to remodel the tumor microenvironment of pancreatic and other treatment-resistant solid tumors.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Nanomedicine drug development
• Tumor microenvironment therapy
• Pancreatic cancer treatment
• Dual-mechanism nanocarrier
• Chemotherapy delivery system

Headquarters

HQ city

Missouri City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Marketing channels2 records

Core offering

OmniNano Pharmaceuticals is developing dual-mechanism nanomedicines engineered to synergistically target tumor cells and the tumor microenvironment. Its lead product, ONP-001, is a dual-mechanism micelle that co-delivers chemotherapy and a stroma-modulating agent in a single nanocarrier, designed to reduce fibrosis, normalize vasculature, relieve hypoxia, deplete cancer stem cells, and kill cancer cells in treatment-resistant solid tumors such as pancreatic cancer.

Product overview

OmniNano Pharmaceuticals is a pharmaceutical company developing dual-mechanism nanomedicines engineered to synergistically target tumor cells and the tumor microenvironment. The company's lead product is ONP-001, a dual-mechanism micelle designed to remodel the dense, fibrotic tumor microenvironment (desmoplastic stroma) in pancreatic cancer and deliver chemotherapy more effectively. ONP-001 represents the company's core technology platform focused on transforming treatment-resistant solid tumors into accessible targets for therapy.

Differentiator

Problem solved

Functional benefit

Products and services

• ONP-001 A dual-mechanism micelle designed to remodel the tumor microenvironment and deliver chemotherapy more effectively for pancreatic cancer. ONP-001 co-delivers chemotherapy and a stroma-modulating agent in a single nanocarrier to reduce fibrosis, normalize vasculature, relieve hypoxia, deplete cancer stem cells, and kill cancer cells.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves3 records

Expansion highlights3 records

Direct peers

• NanoCarrier: Japan-based clinical-stage company developing polymer micelle drug delivery systems for oncology and other diseases. Closely analogous to OmniNano's micelle-based nanocarrier platform for cancer therapy.
• Nanobiotix: Clinical-stage nanoparticle oncology company developing tumor-agnostic nanomedicines (e.g., NBTXR3 radioenhancer). Directly comparable to OmniNano as a nanoparticle-based oncology platform targeting the tumor microenvironment to overcome treatment resistance.
• Celator Pharmaceuticals: Developed CombiPlex, a platform for fixed-ratio combination nanoformulations in oncology (acquired by Jazz Pharmaceuticals). Comparable to OmniNano in using nanomedicine architecture to deliver synergistic drug combinations.
• Starpharma: Develops DEP dendrimer-based nanomedicines for oncology and other indications. Comparable as a platform nanomedicine company engineering drug-delivery carriers to improve therapeutic performance.
• BIND Therapeutics: Developed Accurins, targeted polymeric nanoparticles for oncology (acquired by Pfizer). Relevant historical comparable for OmniNano's targeted nanomedicine platform approach, despite the company no longer operating independently.
• Merrimack Pharmaceuticals: Developed Onivyde (nanoliposomal irinotecan), a nanomedicine formulation approved for pancreatic cancer. Comparable to OmniNano in combining nanomedicine delivery with a focus on pancreatic cancer treatment resistance.

Broad incumbents

• Pfizer: Global pharmaceutical incumbent with extensive oncology franchise, nanoparticle drug delivery capabilities (acquired BIND Therapeutics), and active programs in pancreatic cancer. A likely strategic partner or acquirer for OmniNano at clinical stage.

Emerging players

• CytImmune Sciences: Develops tumor-targeted nanomedicine (Aurix) combining gold nanoparticles with immunotherapy for solid tumors. Comparable as a cancer nanomedicine company focused on remodeling the tumor microenvironment to enable combination therapy.
• Codiak BioSciences: Engineered exosome-based therapeutic platform for oncology and other indications. Comparable as an emerging extracellular-vesicle/nanocarrier oncology platform company pursuing novel drug delivery strategies.
• Nuvation Bio: Clinical-stage oncology company developing multiple targeted therapies across solid tumors. Comparable as a private/emerging oncology platform pursuing differentiation through novel mechanisms in difficult-to-treat tumors.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/omninano-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omninano Pharmaceuticals